[Pain therapy in multiple bone metastases in breast carcinoma with rhenium 186 HEDP].
Therapeutic means for patients with disseminated painful bone metastases in breast cancer are strongly limited. There is a big need of an effective and well tolerated therapy. The aim of this study was to evaluate the efficacy of rhenium-186 HEDP for pain palliation in patients with bone metastases in breast cancer. 17 patients with painful bone metastases taking analgesics received one or more injections of 1295 MB9 rhenium-186 HEDP. In 59% of the patients the therapy resulted in a significant reduction of pain. The duration of pain relief partially hold on up to nine weeks. The main side effects of therapy were a short decrease of platelets and leucocytes and an increase of pain for 1-2 days. As conclusion we found out that therapy with rhenium-186 HEDP can be used complementarily to analgesic therapy and radiation in patients with painful disseminated bone metastases in breast cancer.
Hauswirth
A E
AE
Universitäts-Frauenklinik Bonn-Venusberg.
Palmedo
H
H
Dierke-Dzierzon
C
C
Biersack
H J
HJ
Krebs
D
D
D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy / Q000556:secondary*; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy*; D012968:Etidronic Acid / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010147:Pain Measurement; D010166:Palliative Care; D011788:Quality of Life; D011868:Radioisotopes / Q000627:therapeutic use*; D011877:Radionuclide Imaging; D012211:Rhenium / Q000627:therapeutic use*; D016896:Treatment Outcome
D011868:Radioisotopes; D012211:Rhenium; D012968:Etidronic Acid
Schmerztherapie bei multiplen Knochenmetastasen bei Mammakarzinomen mit Rhenium-186 HEDP.